Form 4: EyePoint Pharmaceuticals' Chief Medical Officer Reports Stock Transactions
SEC Form 4 Filing
Dario A. Paggiarino, Chief Medical Officer of EyePoint Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units to satisfy tax obligations.
Summary
- On March 30, 2024, Dario A. Paggiarino, the Chief Medical Officer of EyePoint Pharmaceuticals, engaged in transactions involving the company's stock.
- These transactions included the acquisition of 5,834, 30,570, and 14,000 shares of common stock through the vesting of restricted stock units.
- Additionally, 15,493, 2,957 and 7,096 shares were disposed of to cover tax withholding requirements related to the vesting of these restricted stock units.
- Following these transactions, Paggiarino directly owns 67,080 shares of EyePoint Pharmaceuticals' common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, with neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they relate to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/09/2023 | Start date for vesting of 5,834 restricted stock units in three ratable annual installments. |
| 01/06/2024 | Start date for vesting of 30,570 restricted stock units in three ratable annual installments. |
| 03/30/2024 | Date of the reported transactions: acquisition and disposal of common stock and restricted stock units. |
| 01/05/2025 | Start date for vesting of 14,000 restricted stock units in three ratable annual installments. |
| 04/02/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.